Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients.
José Luis PiñanaInmaculada HerasTommaso Francesco AielloIrene García-CadenasLourdes VazquezJavier Lopez-JimenezPedro ChorãoCristina ArocaCarolina García-VidalIgnacio ArroyoEva Soler-EspejoLucía López CorralAlejandro Avendaño-PitaAnna ArrufatJ Valentín García-GutiérrezElena ArellanoLorena Hernández-MedinaClara González-SantillanaJulia MorellJose-Ángel Hernández-RivasPaula Rodriguez-GalvezMireia Mico-CerdáManuel GuerreiroDiana CamposDavid NavarroÁngel CedilloRodrigo Martino BofarullCarlos Solanonull nullPublished in: Viruses (2023)
Nirmatrelvir/ritonavir proved to be a safe and effective option for treating mild cases in the outpatient setting, while remdesivir was preferred for severe cases, where corticosteroids and co-infection significantly predicted worse outcomes. Despite antiviral therapy, prolonged shedding remains a matter of concern.
Keyphrases